Coagulants Market (2026 - 2033)

Coagulants Market Summary

The global coagulants market size was valued at USD 12.0 billion in 2025 and is projected to grow from USD 12.9 billion in 2026 to USD 23.6 billion by 2033, at a CAGR of 8.0% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 40.0% in 2025. The increasing volume of surgeries originating from trauma incidents is the primary growth driver for this industry.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

A growing number of new cases related to conditions such as Hemophilia, von Willebrand Disease, anticoagulant overdose, traumatic hemorrhage, and others are expected to further growth in demand for coagulants across the regional market.

An increasing number of individuals on prescribed medication of anticoagulants is a matter of concern. When these individuals experience falls, injuries, accidents, or require unexpected surgeries, compromised clotting often escalates into uncontrolled hemorrhages that require immediate medical intervention. In such cases, medical professionals rely on systemic coagulants for improved outcomes. The rising volume of complex surgical procedures has been strengthening the growth potential of the coagulants industry. The growing number of surgeries has resulted in increasing requirements associated with intraoperative bleeding control, localized tissue sealing, and perioperative blood management.

Increased trauma and emergency room incidents, such as road accidents, industrial mishaps, and violent traumas, are expected to shape further growth of this market in the coming years. For instance, according to the WHO, every year, nearly 20 to 50 million individuals suffer non-fatal injuries due to road traffic accidents. The growing number of injuries, primarily associated with road accidents, industrial mishaps, calamities, and more, is expected to increase the demand for coagulants in the coming years.

Analyst Perspective

The global coagulants industry is experiencing a structural surge in demand as the demographic shift toward an aging population accelerates worldwide and the sheer volume of complex surgical interventions rises. Furthermore, a substantial portion of these older patients are on long-term Direct Oral Anticoagulants (DOACs) or antiplatelet therapies for chronic cardiovascular conditions. This widespread use of blood thinners creates a critical clinical challenge, requiring hospitals to maintain a robust supply of advanced coagulant reversal agents and localized hemostats to manage emergency bleeding and prevent intraoperative complications. Simultaneously, the continuous evolution of surgical techniques is redefining how blood loss is managed in operating rooms. The rapid adoption of minimally invasive surgeries (MIS) and robotic-assisted procedures has made traditional manual compression or suturing difficult due to restricted physical access through narrow laparoscopic ports.

Product Insights

The systemic coagulants segment led the market with the largest revenue share of 43.0% in 2025. The growth of this segment is primarily influenced by the factors such as the rise in bleeding disorders, surgeries, and trauma incidents. Vitamin K is essential for blood clotting, treating deficiencies, or counteracting anticoagulant overdoses. Protamine reverses heparin's effects during surgery, while Desmopressin is used to treat conditions like von Willebrand disease by boosting clot formation. Fibrinogen is crucial for managing conditions or significant loss in surgeries. Tranexamic acid is becoming popular for its effectiveness in bleeding control.

The hemostatics segment is projected to grow at a significant CAGR over the forecast period, driven by the increasing number of surgeries worldwide. Surgeries often need hemostatic agents to control bleeding and promote quicker wound healing, boosting the demand for these products. Advancements in surgical techniques and more complex procedures increase the need for innovative hemostatic products. In April 2025, Baxter International launches a room-temperature version of HEMOPATCH Sealing Hemostat (absorbable collagen pad) in Europe market. Such developments highlight the growth potential of this segment.

Application Insights

The surgeries segment led the market with the largest revenue share of 65.0% in 2025. The segment growth is driven by the global increase in surgical procedures. The growing number of elective and emergency surgeries across specialties such as orthopedics, neurology, and general surgery is boosting demand. Also, surgical advancements have led to more complex surgeries, requiring effective hemostasis management.

The trauma cases segment is anticipated to grow at a significant CAGR during the forecast period. The trauma cases segment is driven by factors including an increase in road accidents, natural disasters, violence-related injuries, and military conflicts around the world. Trauma cases typically involve significant losing blood that needs quick action to prevent hemorrhagic shock and enhance patient outcomes. Coagulants play a crucial role in managing traumatic losing blood, as they facilitate blood clotting and effectively control hemorrhage. This is pivotal in emergency treatments, where quickly stopping the flow of blood can save lives.

Route of Administration Insights

The parenteral administration segment led the market with the largest revenue share of over 55.0% in 2025. Parenteral administration, involving injections directly into the body via routes such as intravenous, intramuscular, or subcutaneous, is crucial. A significant growth driver for parenteral administration is the rising prevalence of coagulants disorders needing immediate and accurate coagulant delivery. This method provides rapid action and high bioavailability, which is important in emergencies for rapid clotting. Advancements in drug delivery technologies have improved the safety and effectiveness of parenteral methods, boosting their use in treatments. The rising number of blood loss cases has heightened demand.

In April 2026, Novo Nordisk published Phase III FRONTIER2 results for denecemig (Mim8), an investigational once-weekly or once-monthly subcutaneous therapy for hemophilia A. This study demonstrates significant reductions in annualized bleeding rates among patients aged 12 years and older, highlighting the continued reliance on parenteral administration for the delivery of advanced coagulation therapies.

The topical administration is anticipated to grow at a significant CAGR over the forecast period. Topical administration, involving the direct application of medications to skin or mucous membranes, is a key area. This method is used primarily for localized treatment of various skin conditions, such as wounds, ulcers, and hematomas, by using clotting agents to aid healing and limit excessive blood loss.

The growth of topical administration is significantly driven by its convenience and non-invasive nature, making it a preferred option over systemic routes such as oral or injectable administration. Patients often choose topical treatments for their simplicity and lower risk of systemic side effects. There's a growing preference among healthcare professionals for topical hemostatic agents for their precise effectiveness without affecting the whole circulatory system.

Regional Insights

North America dominated the global coagulants market with the largest revenue share of 40.0% in 2025. In North America, there is an increasing prevalence of von Willebrand disease and other blood loss diseases that require coagulation factors for treatment. The aging population in North America contributes to the demand for treatments due to age-related conditions that affect blood clotting. In addition, advancements in medical technology and research leading to the development of novel coagulation therapies drive growth.

To learn more about this report, Download Free Sample Report

For instance, the recombinant factor product NovoSeven RT for hemophilia patients with blood loss episodes in hemophilia A and B with inhibitors showed 93% efficacy across 227 bleeds and 90% across 518 severe blood loss episodes involving various sites. Improved healthcare infrastructure, awareness about medical conditions, and favorable government initiatives further propel the expansion in North America.

U.S. Coagulants Market Trends

The coagulants market in the U.S. accounted for the largest market revenue share in North America in 2025, and the demand is rising for coagulation factor concentrates, which play a crucial role in treating blood disorders like hemophilia, von Willebrand disease, and disseminated intravascular coagulation (DIC). Investments in R&D and initiatives to improve access to therapies are expected to positively impact the industry. Emerging trends include the increasing adoption of pharmacy-based comprehensive coagulation management programs that combine medication delivery, remote monitoring, and telehealth consultations to enhance treatment convenience and personalization for patients with chronic blood loss disorders.

Europe Coagulants Market Trends

The coagulants market in Europe is anticipated to grow at a lucrative CAGR during the forecast period. There is a notable trend towards the development and adoption of advanced therapies for various disorders. The Hemophilia Society reports that blood loss disorders affect roughly one in every 2,000 people in the UK and are typically inherited. The most prevalent among these is von Willebrand Disorder (VWD), with current diagnoses including 7,071 women and 4,081 men, though many cases likely go undetected. There is a rise in demand for recombinant clotting factors to address hemophilia A and B. Innovations in gene therapy for hemophilia are gaining momentum, with promising clinical trials showing potential for long-term management of this disorder.

On the political front, one notable trend impacting Europe is the regulatory environment surrounding the approval and reimbursement of medical products. The European Medicines Agency (EMA) plays a crucial role in regulating the marketing authorization of pharmaceuticals within the European Union. Changes in regulations, including those related to clinical trial requirements, pricing and reimbursement policies, and post-surveillance, can significantly influence industry dynamics and access to innovative therapies. Political decisions regarding healthcare funding, public health priorities, and trade agreements also directly affect the availability and affordability of products in Europe.

Asia Pacific Coagulants Market Trends

The coagulants market in the Asia Pacific is anticipated to grow at the fastest CAGR over the forecast period. The Countries like Japan, China, and India are at the forefront due to their large population bases and rising healthcare expenditures. The demand for clotting factors and other coagulation therapies is on the rise as awareness about these disorders increases and access to healthcare improves across the region. For instance, in Japan, where hemophilia A is prevalent, there is an increased adoption of recombinant factor VIII products.

Key Coagulants Company Insights

Some of the key market players operating in the coagulants industry include Johnson & Johnson, Baxter International Inc., Pfizer Inc., and Bristol-Myers Squibb Company. These companies are making significant infrastructure investments, which enable them to develop, manufacture, and commercialize worldwide. In addition, to increase their global presence, companies enter into several strategic partnerships with distributors and other companies.

Key Coagulants Companies

The following key companies have been profiled for this study on the global coagulants market.

• Johnson & Johnson

• Baxter.

• Pfizer Inc.

• Bristol-Myers Squibb Company

• Sanofi

• Bayer AG

• Novo Nordisk A/S

• CSL

• Octapharma AG

• Grifols, S.A.

• Amgen Inc.

• Takeda Pharmaceutical Company Limited

Recent Developments

• In September 2025, VarmX announced its latest collaboration with CSL to support development activities related to its lead asset. The VMX C001 is a newly designed treatment for the restoration of blood coagulation in individuals who require emergency surgery or experience bleeding while on FXa DOACs.
• In January 2026, Rentschler Biopharma and VarmX announced expansion of their partnership for late‑stage and manufacturing processes related to VMX-C001, with the plan to transfer manufacturing activities from Rentschler Biopharma's site in Laupheim (Germany) to Milford, MA (USA).

Global Coagulants Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global coagulants market report based on product, application, route of administration, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)

  • Topical Coagulants

  • Absorbable Gelatin

  • Oxidized Cellulose

  • Microfibrillar Collagen

  • Other topical coagulants

  • Systemic Coagulants

  • Vitamin K

  • Protamine

  • Desmopressin

  • Fibrinogen

  • Other systemic coagulants

  • Hemostatics

• Application Outlook (Revenue, USD Million, 2021 - 2033)

  • Surgeries

  • Trauma Cases

  • Hemophilia

  • Bleeding Disorders

  • Other Applications

• Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)

  • Topical Administration

  • Parenteral Administration

  • Oral Administration

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • China

    • Japan

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa

    • South Africa

    • Saudi Arabia

    • Kuwait

    • UAE